<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-351 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-351</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-351</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-6.html">extraction-schema-6</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing Asian and non-Asian populations, and any proposed explanations for ethnic differences.</div>
                <p><strong>Paper ID:</strong> paper-7d325a7b5d9b85e562426d3b1fbf5539e54d3829</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/7d325a7b5d9b85e562426d3b1fbf5539e54d3829" target="_blank">EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression.</a></p>
                <p><strong>Paper Venue:</strong> Journal of Molecular Diagnostics</p>
                <p><strong>Paper TL;DR:</strong> Results indicate that EGFR amplification, preferentially of the mutant allele, often accompanies EGFR mutation, whereas EGFR immunohistochemical staining associates with amplification but cannot predict EG FR mutation status.</p>
                <p><strong>Cost:</strong> 0.009</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e351.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e351.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing Asian and non-Asian populations, and any proposed explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Li et al. 2008 (MSKCC)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>EGFR Mutations in Lung Adenocarcinomas: Clinical Testing Experience and Relationship to EGFR Gene Copy Number and Immunohistochemical Expression</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A prospective clinical testing study of 334 mainly adenocarcinoma lung cancer cases at Memorial Sloan-Kettering Cancer Center reporting EGFR exon 19 deletions and exon 21 L858R frequencies, their associations with EGFR amplification/protein expression, and clinical correlates (smoking, sex).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>EGFR Mutations in Lung Adenocarcinomas: Clinical Testing Experience and Relationship to EGFR Gene Copy Number and Immunohistochemical Expression</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_ethnicity</strong></td>
                            <td>North American / mixed (ethnicity not specifically enumerated; authors note possible referral bias including ethnicity)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_location</strong></td>
                            <td>United States (Memorial Sloan-Kettering Cancer Center, New York)</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td>334</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>23% overall (78 of 334 cases); among mutations 71% exon 19 deletions (55/78) and 29% exon 21 L858R (23/78).</td>
                        </tr>
                        <tr>
                            <td><strong>specific_mutation_types</strong></td>
                            <td>Predominantly exon 19 in-frame deletions (reported deletion sizes: 9 bp, 15 bp, 18 bp, 24 bp) and exon 21 L858R point mutation; the assays targeted these two hotspot mutations (~90% of EGFR mutations).</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_with_other_ethnicities</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>comparative_frequency_data</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status_correlation</strong></td>
                            <td>EGFR mutations strongly associated with never-smoker status: in the 60-case tissue microarray subset 59% (17/29) of mutated cases were never-smokers vs 13% (4/31) of non-mutated cases (P = 0.0003).</td>
                        </tr>
                        <tr>
                            <td><strong>gender_correlation</strong></td>
                            <td>EGFR mutations were more common in females (majority â€” 64% of mutation-positive patients were women in the overall series).</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_genetic</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_environmental</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_lifestyle</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_other</strong></td>
                            <td>Authors propose detection/referral and methodological explanations rather than biological ethnic mechanisms: (1) referral bias/enrichment of the tested North American population by histology, smoking history, or ethnicity may elevate observed mutation frequency relative to unselected populations; (2) assay sensitivity differences (PCR-based assays used here are more sensitive than direct sequencing) and dilution by admixed non-neoplastic cells can cause under-detection by sequencing, so some apparent ethnic or cohort differences may reflect testing methods; (3) association of EGFR amplification with mutation suggests that reported predictive value of amplification may be secondary to its correlation with mutation.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_histology</strong></td>
                            <td>Primarily lung adenocarcinoma (>90%), including bronchioloalveolar carcinoma (BAC) or adenocarcinoma with BAC features.</td>
                        </tr>
                        <tr>
                            <td><strong>response_to_egfr_inhibitors</strong></td>
                            <td>Paper reiterates that presence of EGFR-activating mutations predicts high sensitivity to EGFR TKIs (aggregate ~75% response rate cited from clinical trials), but provides no ethnicity-stratified response rates.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression.', 'publication_date_yy_mm': '2008-05'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib <em>(Rating: 2)</em></li>
                <li>EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy <em>(Rating: 2)</em></li>
                <li>EGF receptor gene mutations are common in lung cancers from "never smokers" and correlate with sensitivity of tumors to gefitinib (Iressa) and erlotinib (Tarceva) <em>(Rating: 2)</em></li>
                <li>Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers <em>(Rating: 2)</em></li>
                <li>Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer <em>(Rating: 1)</em></li>
                <li>Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer <em>(Rating: 2)</em></li>
                <li>Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer <em>(Rating: 1)</em></li>
                <li>Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>